Compare Stocks: BIAF, BMGL, MGRX, and AIDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIDX 20/20 Biolabs	$0.59 -3.3%	$0.53	$0.40 ▼ $50.00	$7.81M	N/A	99,234 shs	131,167 shs
BIAF bioAffinity Technologies	$15.27 +19.5%	$9.08	$4.56 ▼ $202.50	$7.57M	-1.11	6.21 million shs	19.66 million shs
BMGL Basel Medical Group	$4.77 -0.3%	$5.77	$4.17 ▼ $25.80	$7.48M	0.26	19,280 shs	559 shs
MGRX Mangoceuticals	$0.41 +5.3%	$0.44	$0.16 ▼ $2.75	$8.42M	2.04	3.53 million shs	519,687 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIDX 20/20 Biolabs	-3.27%	-5.21%	+34.04%	-26.25%	+59,149,900.00%
BIAF bioAffinity Technologies	+19.48%	+213.55%	+92.15%	-41.16%	-86.26%
BMGL Basel Medical Group	-0.42%	-9.06%	-13.36%	-27.07%	-79.84%
MGRX Mangoceuticals	+5.30%	+2.19%	-3.41%	+15.13%	-81.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIDX 20/20 Biolabs	$0.59 -3.3%	$0.53	$0.40 ▼ $50.00	$7.81M	N/A	99,234 shs	131,167 shs
BIAF bioAffinity Technologies	$15.27 +19.5%	$9.08	$4.56 ▼ $202.50	$7.57M	-1.11	6.21 million shs	19.66 million shs
BMGL Basel Medical Group	$4.77 -0.3%	$5.77	$4.17 ▼ $25.80	$7.48M	0.26	19,280 shs	559 shs
MGRX Mangoceuticals	$0.41 +5.3%	$0.44	$0.16 ▼ $2.75	$8.42M	2.04	3.53 million shs	519,687 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIDX 20/20 Biolabs	-3.27%	-5.21%	+34.04%	-26.25%	+59,149,900.00%
BIAF bioAffinity Technologies	+19.48%	+213.55%	+92.15%	-41.16%	-86.26%
BMGL Basel Medical Group	-0.42%	-9.06%	-13.36%	-27.07%	-79.84%
MGRX Mangoceuticals	+5.30%	+2.19%	-3.41%	+15.13%	-81.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIDX 20/20 Biolabs	2.00	Hold	$5.00	745.31% Upside
BIAF bioAffinity Technologies	1.00	Sell	N/A	N/A
BMGL Basel Medical Group	1.00	Sell	N/A	N/A
MGRX Mangoceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BIAF, BMGL, MGRX, and AIDX Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/21/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	AIDX 20/20 Biolabs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
8/3/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	BIAF bioAffinity Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/30/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	MGRX Mangoceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/15/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIDX 20/20 Biolabs	$2.05M	3.68	N/A	N/A	$0.13 per share	4.55
BIAF bioAffinity Technologies	$5.85M	1.55	N/A	N/A	$6.36 per share	2.40
BMGL Basel Medical Group	$8.90M	0.84	N/A	N/A	$2.44 per share	1.95
MGRX Mangoceuticals	$460K	19.27	N/A	N/A	$0.58 per share	0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIDX 20/20 Biolabs	-$3.74M	-$0.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BIAF bioAffinity Technologies	-$14.91M	-$109.45	N/A	N/A	N/A	-257.30%	-220.52%	-136.76%	11/18/2026 (Estimated)
BMGL Basel Medical Group	-$9.50M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGRX Mangoceuticals	-$20.64M	-$1.01	N/A	N/A	N/A	-4,794.60%	-96.39%	-89.60%	N/A

Latest BIAF, BMGL, MGRX, and AIDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	AIDX 20/20 Biolabs	N/A	-$0.26	N/A	-$0.26	N/A	$0.73 million
8/13/2026	Q2 2026	MGRX Mangoceuticals	N/A	-$0.09	N/A	-$0.09	N/A	$0.08 million
8/7/2026	Q2 2026	BIAF bioAffinity Technologies	-$31.50	-$0.64	+$30.86	-$9.60	$1.70 million	$1.51 million
6/26/2026	Q2 2026	BMGL Basel Medical Group	N/A	$0.01	N/A	$0.0050	N/A	$3.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIDX 20/20 Biolabs	N/A	N/A	N/A	N/A	N/A
BIAF bioAffinity Technologies	N/A	N/A	N/A	N/A	N/A
BMGL Basel Medical Group	N/A	N/A	N/A	N/A	N/A
MGRX Mangoceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIDX 20/20 Biolabs	N/A	1.99	1.95
BIAF bioAffinity Technologies	0.14	1.44	1.41
BMGL Basel Medical Group	0.93	1.88	1.83
MGRX Mangoceuticals	N/A	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIDX 20/20 Biolabs	N/A
BIAF bioAffinity Technologies	1.64%
BMGL Basel Medical Group	N/A
MGRX Mangoceuticals	56.72%

Insider Ownership

Company	Insider Ownership
AIDX 20/20 Biolabs	29.80%
BIAF bioAffinity Technologies	2.68%
BMGL Basel Medical Group	N/A
MGRX Mangoceuticals	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIDX 20/20 Biolabs	14	12.77 million	8.97 million	N/A
BIAF bioAffinity Technologies	10	592,000	576,000	Not Optionable
BMGL Basel Medical Group	36	1.56 million	N/A	N/A
MGRX Mangoceuticals	3	21.57 million	18.12 million	Not Optionable

BIAF, BMGL, MGRX, and AIDX Headlines

Recent News About These Companies

Mangoceuticals Terminates Planned Business Combination with Nuclea

August 21, 2026 | tipranks.com

MGRX Stock Alert: Halper Sadeh LLC is Investigating Whether Mangoceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 17, 2026 | businesswire.com

Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets

August 13, 2026 | markets.businessinsider.com

Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

August 13, 2026 | globenewswire.com

Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

August 13, 2026 | newsfilecorp.comN

Mangoceuticals’ Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

August 6, 2026 | markets.businessinsider.com

Mangoceuticals (MGRX) stock jumps over 49% after hours: Here's why

August 6, 2026 | msn.com

Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

August 6, 2026 | globenewswire.com

Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

August 6, 2026 | newsfilecorp.comN

Mangoceuticals, Inc.: Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

August 5, 2026 | finanznachrichten.de

Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

August 5, 2026 | finance.yahoo.com

Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development

August 5, 2026 | newsfilecorp.comN

Mangoceuticals' Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

August 5, 2026 | globenewswire.com

Mangoceuticals Wins Nasdaq Extension Amid Nuclea Deal Progress

August 4, 2026 | tipranks.com

Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

August 4, 2026 | globenewswire.com

MGRX surges after Nuclea Energy reverse-merger deal reshapes company story

July 31, 2026 | quiverquant.comQ

Mangoceuticals (MGRX) stock jumps 138% after hours on nuclear reactor deal: Here's why it is trending

July 31, 2026 | msn.com

Mangoceuticals, Inc.: Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

July 30, 2026 | finanznachrichten.de

Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

July 30, 2026 | newsfilecorp.comN

Mangoceuticals Announces Nuclea Energy Business Combination Agreement

July 30, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF, BMGL, MGRX, and AIDX Company Descriptions

20/20 Biolabs NASDAQ:AIDX

$0.59 -0.02 (-3.27%)

As of 09/4/2026 03:58 PM Eastern

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026. Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD. That laboratory also hosts our Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the U.S. without the expense of establishing and operating their own, independent lab. As noted above, during the COVID-19 pandemic, we also provided COVID-19 viral testing using polymerase chain reaction, or PCR, analytical equipment in our clinical laboratory. Our legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. As of the date of this prospectus, we generate revenue from three sources: OneTest for Cancer (primarily as a lab test in the U.S. but we also license our algorithms to overseas labs), BioCheck and from our CLIAx. For each of the nine months ended September 30, 2025 and 2024, sales of OneTest for Cancer accounted for approximately 87% of our revenues, sales of BioCheck accounted for approximately 9% of our revenues, and our CLIAx accounted for approximately 4% of our revenues. For the years ended December 31, 2024 and 2023, sales of OneTest for Cancer accounted for approximately 85% and 65% of our revenues, respectively, sales of BioCheck accounted for approximately 10% and 13% of our revenues, respectively, our CLIAx accounted for approximately 5% and 4% of our revenues, respectively, and COVID-19 testing accounted for approximately 0% and 18% of our revenues, respectively. Our principal executive offices are located in Gaithersburg, MD.

bioAffinity Technologies NASDAQ:BIAF

$15.27 +2.49 (+19.48%)

As of 09/4/2026 04:00 PM Eastern

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Basel Medical Group NASDAQ:BMGL

$4.76 -0.02 (-0.31%)

As of 09/4/2026 03:55 PM Eastern

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.

Mangoceuticals NASDAQ:MGRX

$0.41 +0.02 (+5.30%)

As of 09/4/2026 04:00 PM Eastern

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIAF, BMGL, MGRX, and AIDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIAF, BMGL, MGRX, and AIDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIAF, BMGL, MGRX, and AIDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF, BMGL, MGRX, and AIDX Company Descriptions

20/20 Biolabs NASDAQ:AIDX

bioAffinity Technologies NASDAQ:BIAF

Basel Medical Group NASDAQ:BMGL

Mangoceuticals NASDAQ:MGRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIAF, BMGL, MGRX, and AIDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIAF, BMGL, MGRX, and AIDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIAF, BMGL, MGRX, and AIDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF, BMGL, MGRX, and AIDX Company Descriptions

20/20 Biolabs NASDAQ:AIDX

bioAffinity Technologies NASDAQ:BIAF

Basel Medical Group NASDAQ:BMGL

Mangoceuticals NASDAQ:MGRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools